Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Animals
Breast Neoplasms
/ genetics
Cell Cycle Proteins
/ genetics
Cell Line, Tumor
Drug Delivery Systems
Female
Gene Expression Regulation, Neoplastic
Glucose
/ chemistry
Glucose Transporter Type 1
/ genetics
Gold
/ chemistry
Humans
Metal Nanoparticles
/ chemistry
Mice, Inbred BALB C
Mice, Nude
Neoplastic Stem Cells
/ metabolism
Protein Serine-Threonine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
RNA, Small Interfering
/ administration & dosage
RNAi Therapeutics
Polo-Like Kinase 1
Cancer stem-like cell
Glucose
Gold nanoparticle
Polyion complex
siRNA delivery
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 02 2019
10 02 2019
Historique:
received:
30
07
2018
revised:
18
12
2018
accepted:
07
01
2019
pubmed:
15
1
2019
medline:
19
5
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Cancer stem-like cells (CSCs) treatment is a plausible strategy for enhanced cancer therapy. Here we report a glucose-installed sub-50-nm nanocarrier for the targeted delivery of small interfering RNA (siRNA) to CSCs through selective recognition of the glucose ligand to the glucose transporter 1 (GLUT1) overexpressed on the CSC surface. The siRNA nanocarrier was constructed via a two-step assembling process. First, a glucose-installed poly(ethylene glycol)-block-poly(l-lysine) modified with lipoic acid (LA) at the ω-end (Glu-PEG-PLL-LA) was associated with a single siRNA to form a unimer polyion complex (uPIC). Second, a 20 nm gold nanoparticle (AuNP) was decorated with ~65 uPICs through AuS bonding. The glucose-installed targeted nanoparticles (Glu-NPs) exhibited higher cellular uptake of siRNA payloads in a spheroid breast cancer (MBA-MB-231) cell culture compared with glucose-unconjugated control nanoparticles (MeO-NPs). Notably, the Glu-NPs became more efficiently internalized into the CSC fraction, which was defined by aldehyde dehydrogenase (ALDH) activity assay, than the other fractions, probably due to the higher GLUT1 expression level on the CSCs. The Glu-NPs elicited significantly enhanced gene silencing in a CSC-rich orthotopic MDA-MB-231 tumor tissue following systemic administration to tumor-bearing mice. Ultimately, the repeated administrations of polo-like kinase 1 (PLK1) siRNA-loaded Glu-NPs significantly suppressed the growth of orthotopic MDA-MB-231 tumors. These results demonstrate that Glu-NP is a promising nanocarrier design for CSC-targeted cancer treatment.
Identifiants
pubmed: 30639386
pii: S0168-3659(19)30022-7
doi: 10.1016/j.jconrel.2019.01.006
pii:
doi:
Substances chimiques
Cell Cycle Proteins
0
Glucose Transporter Type 1
0
Proto-Oncogene Proteins
0
RNA, Small Interfering
0
SLC2A1 protein, human
0
Gold
7440-57-5
Protein Serine-Threonine Kinases
EC 2.7.11.1
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-277Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.